New treatment option for Canadians living with rare and serious X-chromosome linked congenital bleeding disorder MISSISSAUGA, ON — /CNW/ — Health Canada has approved Alhemo™, the first anti-tissue factor pathway inhibitor… Read More
VANCOUVER, BC — (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that… Read More
In-depth characterization of CD3-binding antibodies reveals molecules with binding and functional properties that are differentiated from antibodies commonly used for T-cell engager development Discovery of antibodies with high specificity for… Read More
Partnership will strengthen research collaborations between the two countries MONTRÉAL, QC — Today, the Honourable François‑Philippe Champagne, Minister of Innovation, Science and Industry, and Guy Parmelin, Swiss Federal Councillor for Economic… Read More
Indications under review include prevention of RSV in infants from birth through 6 months of age by immunization of pregnant individuals, and in individuals 60 years of age and older…. Read More
